Literature DB >> 29362882

Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.

Abhishek Mitra1, Esha Pai1, Rohit Dusane2, Priya Ranganathan3, Ashwin DeSouza1, Mahesh Goel1, Shailesh V Shrikhande4.   

Abstract

PURPOSE: Extended pancreatectomy aimed at R0 resection of pancreatic tumors with adjacent vessel and organ involvement may be the only option for cure. This study was done with an objective to analyze the short- and long-term outcomes of extended pancreatic resections.
METHODS: All pancreatectomies performed between 2006 and 2015 were included. The pancreatectomies were classified as standard or extended, as per the International Study Group for Pancreatic Surgery. All surgical complications and terminologies were according to Clavien-Dindo classification and International Study Group for Pancreatic Surgery guidelines. Morbidity and mortality were primary outcomes and disease-free survival was a secondary outcome.
RESULTS: Sixty-three extended and 620 standard pancreatectomies were performed. Major morbidity (Clavien grades III, IV and V) (37 vs. 29%, p = 0.21) and mortality (6 vs. 4%, p = 0.3) for extended pancreatectomies were comparable to those for standard pancreatectomies. Blood loss > 855 ml, need for blood transfusion, and tumor size were independent risk factors for morbidity, and the latter two for mortality. Standard pancreatectomies were associated with better 3-year disease-free survival than extended pancreatectomies (67 vs. 41%, p < 0.001). Extended pancreatectomies resulted in a significantly better median disease-free survival for non-pancreatic adenocarcinoma vs. pancreatic adenocarcinoma (33.3 vs. 9.5 months, p = 0.01).
CONCLUSION: Extended pancreatectomies resulted in similar peri-operative morbidity and mortality compared to standard pancreatectomies. Although the survival of patients undergoing these complex procedures is inferior to standard pancreatectomies, they should be undertaken not only in selected cases of pancreatic cancer but even more so in other complex pancreatic tumors.

Entities:  

Keywords:  Extended; Outcome; Pancreatectomy; Survival

Mesh:

Year:  2018        PMID: 29362882     DOI: 10.1007/s00423-018-1653-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  46 in total

1.  Trends in the treatment and outcome of pancreatic cancer in the United States.

Authors:  Nancy N Baxter; Bryan A Whitson; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2007-01-17       Impact factor: 5.344

2.  Declaration of Helsinki. Ethical principles for medical research involving human subjects.

Authors: 
Journal:  J Indian Med Assoc       Date:  2009-06

3.  Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.

Authors:  Reena Ravikumar; Caroline Sabin; Mohammad Abu Hilal; Simon Bramhall; Steven White; Stephen Wigmore; Charles J Imber; Giuseppe Fusai
Journal:  J Am Coll Surg       Date:  2013-11-27       Impact factor: 6.113

4.  Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis.

Authors:  J Klempnauer; G J Ridder; H Bektas; R Pichlmayr
Journal:  Oncology       Date:  1996 Jan-Feb       Impact factor: 2.935

5.  Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy.

Authors:  P Jagannath; V Dhir; S Shrikhande; R C Shah; P Mullerpatan; K M Mohandas
Journal:  Br J Surg       Date:  2005-03       Impact factor: 6.939

6.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

7.  Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results.

Authors:  J G Fortner
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

8.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

9.  Evolution of pancreatoduodenectomy in a tertiary cancer center in India: improved results from service reconfiguration.

Authors:  Shailesh V Shrikhande; Savio George Barreto; B A Somashekar; Kunal Suradkar; Guruprasad S Shetty; Sanjay Talole; Bhawna Sirohi; Mahesh Goel; Parul J Shukla
Journal:  Pancreatology       Date:  2012-11-10       Impact factor: 3.996

10.  Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS).

Authors:  Werner Hartwig; Charles M Vollmer; Abe Fingerhut; Charles J Yeo; John P Neoptolemos; Mustapha Adham; Ake Andrén-Sandberg; Horacio J Asbun; Claudio Bassi; Max Bockhorn; Richard Charnley; Kevin C Conlon; Christos Dervenis; Laureano Fernandez-Cruz; Helmut Friess; Dirk J Gouma; Clem W Imrie; Keith D Lillemoe; Miroslav N Milićević; Marco Montorsi; Shailesh V Shrikhande; Yogesh K Vashist; Jakob R Izbicki; Markus W Büchler
Journal:  Surgery       Date:  2014-02-20       Impact factor: 3.982

View more
  2 in total

1.  Single-layer continuous duct-to-mucosa pancreaticojejunostomy: "how we do it".

Authors:  Qun Chen; Peng Shen; Pengfei Wu; Baobao Cai; Jie Yin; Jishu Wei; Taoyue Yang; Zipeng Lu; Yi Miao; Kuirong Jiang
Journal:  Langenbecks Arch Surg       Date:  2022-05-30       Impact factor: 2.895

2.  Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma.

Authors:  Hu Ren; Chao-Rui Wu; Saderbieke Aimaiti; Cheng-Feng Wang
Journal:  Oncol Lett       Date:  2020-03-29       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.